Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DE61WB
|
|||
| Drug Name |
NGM707
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 2 | [1] | |
| Company |
NGM Biopharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte immunoglobulin-like receptor B2 (LILRB2) | Target Info | Antagonist | [2] |
| Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) | Target Info | Antagonist | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04913337) A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of NGM Biopharma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.